Probable Case Of Ebola-Like Marburg Virus In Guinea
Marburg virus may have been identified for the first time in West Africa. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 7, 2021 Category: Pharmaceuticals Authors: Judy Stone, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news
Anti-tumor agent from the intestine
(University of W ü rzburg) Certain metabolites of bacteria from the intestine make immune cells more aggressive as a new study conducted by scientists from german universities in W ü rzburg and Marburg reveals. The findings could help improve cancer therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 9, 2021 Category: International Medicine & Public Health Source Type: news
Blocking viruses' exit strategy
(University of Pennsylvania) The Marburg virus, a relative of Ebola, likewise causes a dangerous and often fatal disease. In a study co-led by the University of Pennsylvania's Ronald Harty, an experimental antiviral drug, which prevents the virus from exiting host cells and spreading to new cells, showed promising results. The researchers are also encouraged by similarities in the drug's response against SARS-CoV-2, the virus that causes COVID-19. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 6, 2021 Category: Biology Source Type: news
Exclusive: Inside the Facilities Making the World ’s Most Prevalent COVID-19 Vaccine
If you’ve been vaccinated for COVID-19, chances are pretty high that you’re benefiting from a product made by BioNTech. The German biotech company, co-founded by a husband-and-wife team of scientists, developed the vaccine that became not only the first to earn authorization in the U.S. for COVID-19 in December but also the first ever based on a new technology involving the genetic material mRNA.
In interviews in December and March, co-founders Ugur Sahin and Ozlem Tureci spoke about their whirlwind year and their partnership with U.S. pharmaceutical company Pfizer to test and manufacture the vaccine. Over thre...
Source: TIME: Health - April 19, 2021 Category: Consumer Health News Authors: Alice Park and Aryn Baker/Marburg, Germany Tags: Uncategorized COVID-19 Exclusive feature longform Magazine photography Source Type: news
‘Where the magic happens’ — inside BioNTech’s innovative vaccine plant
Marburg facility in Germany is first to make approved coronavirus vaccine using mRNA technology (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 2, 2021 Category: Pharmaceuticals Source Type: news
BioNTech-Pfizer raise 2021 vaccine output goal to 2.5 billion doses
Pfizer previously said the partners would likely produce between 2.3 billion and 2.4 billion doses in 2021. BioNTech cited its new facility in the German city of Marburg and an expansion of the pair's network of third-party manufacturers and suppliers as drivers of the larger volumes. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 30, 2021 Category: Pharmaceuticals Source Type: news
BioNTech provides update on vaccine production status at Marburg manufacturing site
BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part of the process, EMA has approved the production of the drug substance, the mRNA, at the Marburg site over the course of this week. (Source: World Pharma News)
Source: World Pharma News - March 26, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news
Combination therapy protects against advanced Marburg virus disease
(University of Texas Medical Branch at Galveston) A new study conducted at the Galveston National Laboratory at the The University of Texas Medical Branch at Galveston (UTMB) has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus. The study was published today in Nature Communications. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 25, 2021 Category: Infectious Diseases Source Type: news
The medieval German town at the heart of the fight against Covid
BioNTech’s vaccine facility in Marburg will produce 750m doses a year (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 22, 2021 Category: Pharmaceuticals Source Type: news
New study suggests better approach in search for COVID-19 drugs
(University of Kent) Research from the University of Kent, Goethe-University in Frankfurt am Main, and the Philipps-University in Marburg has provided crucial insights into the biological composition of SARS-CoV-2, the cause of COVID-19, revealing vital clues for the discovery of antiviral drugs. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 11, 2021 Category: Infectious Diseases Source Type: news
New drug target for Ebola, Marburg viruses
(University of Illinois at Chicago) Researchers have identified a previously unknown site on the filovirus glycoprotein to which small drug molecules can bind and prevent infection -- blocking both sites may be a more effective treatment while reducing the risk of side effects. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 8, 2021 Category: Infectious Diseases Source Type: news
SARS-CoV-2-Neutralizing-Antibody-enters-Clinical-Phase
New SARS-CoV-2 Neutralizing Antibody enters Clinical PhaseCologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim collaborate on potential COVID-19 therapy and preventionBI 767551 (DZIF-10c) is a potent anti-SARS-CoV-2 antibody that has shown promising virus neutralizing properties in pre-clinical researchPhase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 18, 2020 Category: Research Source Type: news
New SARS-CoV-2 neutralizing antibody enters clinical phase
(German Center for Infection Research) Cologne University Hospital, University of Marburg, the German Center for Infection Research and Boehringer Ingelheim collaborate on potential COVID-19 therapy and prevention (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 18, 2020 Category: Infectious Diseases Source Type: news
Water at the end of the tunnel
(Max Planck Institute for Marine Microbiology) We humans need oxygen to breath - for a lot of microbes it is a lethal poison. That is why microorganisms have developed ways to render oxygen molecules harmless. Microbiologists from Bremen, Marburg and Grenoble have now succeeded in decrypting such a mechanism. They show, how methane-generating microbes transform oxygen into water without causing any damage to the cell. These findings are relevant for future bio-inspired processes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 28, 2020 Category: Biology Source Type: news
Researcher gets $2.94 million federal grant to study unique features of Ebola and marburg viruses
(Georgia State University) Dr. Christopher Basler, professor and director of the Center for Microbial Pathogenesis in the Institute for Biomedical Sciences at Georgia State University, has received a five-year, $2.94 million federal grant to study unique features of Ebola and Marburg viruses that control how the virus family expresses its genes and escapes immune responses. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 15, 2020 Category: Infectious Diseases Source Type: news
